Human Longevity, Inc. (HLI), a San Francisco-based precision medicine company, has raised $39.8M in a series B funding round to advance its AI-driven health risk insight and recommendation platform. The new capital will also allow the company to introduce new longevity-focused technologies and services.
Co-founded in 2013 by Dr J Craig Venter, a genomic pioneer, the company focuses on leveraging innovative technologies to extend human health and well-being beyond the traditional treatment approach, which focuses only on treating diseases.
The company’s latest round was spearheaded by TVM Capital Healthcare, with continued support from existing investors, including Emerging Technology Partners and Panacea Venture.
Shifting Healthcare Approach
HLI recently announced entering a strategic collaboration with the Chopra Foundation to shift the healthcare approach from focusing on treatment based on symptoms to a more personalized, preventive, and proactive.
The company’s platform analyses health data from its clients to help in early disease detection for more targeted and personalized medical interventions that can help extend life and health span.
Early detection of life-threatening health risks such as neurodegenerative illnesses, cancer, metabolic conditions, and cardiovascular diseases is not only life-saving but also lowers medical costs. The approach can help improve patient’s health outcomes and healthcare resource management.
Currently operating health assessment facilities in San Francisco and San Diego, HLI will use the new funding to expand its services globally, with new clinics expected to be set up in new locations in Europe, Asia, and Saudi Arabia, as well as in other GCC countries.
